Skip to main content

Table 2 Bronchoalveolar lavage fluid cytology

From: Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma

 

SCT mean (SD)

DEX mean (SD)

SCT T2 versus T1 difference

DEX versus SCT for T2 and T1 difference

 

T1

T2

T1

T2

Effecta [95% CI]

P value (adjusted)

Effectb [95% CI]

P value (adjusted)

TCC*

0.437 (0.256)

0.483 (0.261)

0.650 (0.382)

0.540 (0.359)

1.033 [0.681; 1.568]

0.87 (0.9)

0.848 [0.492; 1.463]

0.53 (0.7)

Mac (%)

34.580 (4.693)

34.510 (7.563)

27.930 (7.932)

35.520 (10.653)

2.665 [-3.611; 8.941]

0.38 (0.5)

2.190 [-5.452; 9.831]

0.60 (0.7)

Neut (%)*

33.950 (11.060)

31.310 (14.240)

39.550 (24.475)

33.820 (16.305)

0.886 [0.674; 1.164]

0.36 (0.5)

1.058 [0.733; 1.526]

0.75 (0.8)

Lymph (%)

31.390 (9.217)

31.550 (10.630)

29.460 (17.911)

32.860 (14.146)

0.527 [-6.740; 7.795]

0.88 (0.9)

2.506 [-7.217; 12.228]

0.59 (0.7)

Eos (%)

0.870 (1.421)

1.930 (3.804)

0.580 (1.573)

0.000 (0.000)

1.148 [-0.299; 2.595]

0.11 (0.3)

-1.816 [-3.670; 0.038]

0.05 (0.2)

Mast (%)

0.410 (0.534)

0.910 (1.249)

0.620 (1.219)

0.180 (0.569)

0.406 [-0.337; 1.148]

0.27 (0.4)

-0.751 [-1.635; 0.133]

0.09 (0.2)

  1. TCC (WBC/mm3), mean total cell count (BALf)
  2. Mac macrophages, Neut neutrophils, Lymph lymphocytes, Eos eosinophils, Mast mast cells, SCT Stem cell treatment, DEX Dexamethasone treatment, T1 Beginning of treatment, T2 End of treatment
  3. *Logarithmic transformation (descriptive values are reported on the original scale)
  4. aYT2–YT1 (non-transformed outcome) or YT2/YT1 (logarithmic transformation) for SCT as estimated with linear mixed effects model
  5. b(YT2–YT1)DEX-(YT2–YT1)SCT (non-transformed outcome) or (YT2/YT1)DEX/(YT2/YT1)SCT (logarithmic transformation) as estimated with linear mixed effects model. Additional data are available in graphical form in the Additional file 2: Figure S2